Vinati Q1: revenue +28% YoY but margin squeeze holds consolidated PAT growth to 4.5%
PAT +4.5% YoY · revenue +28.4% · margins compressing
₹695.91 Cr
+28.4% YoY
₹108.86 Cr
+4.5% YoY
15.44%
-3.5pp YoY
₹10.5
Vinati Organics opened FY27 with a strong topline but a visibly softer bottom line. Consolidated revenue rose ~28% YoY to ₹695.91 Cr (from ₹541.97 Cr) and ~15% QoQ, yet consolidated PAT grew only ~4.5% YoY to ₹108.86 Cr and actually fell ~12% sequentially from ₹123.86 Cr. Standalone told a slightly better story — PAT ₹123.56 Cr (+9.6% YoY) on revenue ₹697.75 Cr — the ~5-point growth gap versus consolidated reflecting drag from the wholly-owned subsidiaries (Veeral Organics, Vinati USA) still in their investment phase.
Q1 FY-2027 vs prior quarters
The quarter's real signal is margin compression. Consolidated operating margin fell to ~24.5% from ~29.5% a year ago and ~28.2% last quarter, and net margin dropped to ~15.6% from ~19.0% YoY. The squeeze sits on the input line: cost of materials consumed jumped to ₹380.62 Cr (54.7% of sales vs ~51.9% year-ago) and power & fuel rose to ₹49.43 Cr (from ₹38.15 Cr) — raw-material and energy cost inflation outrunning the price/volume gain. At ~24.5% EBITDA, the print undershoots management's own 26-27% FY27 margin guidance from the Q4 concall, even as the 28% revenue jump is consistent with its ~15% volume-growth ambition.
The stock went into the print at ₹1,315.4, down 1.5% over the past month of trading.
For context: revenue is at a 6-quarter high.
What the summary numbers don't show
Standalone stronger — PAT ₹123.56 Cr (+9.6% YoY), EPS ₹11.92 — consolidated dragged by subsidiary investment phase
Management is targeting approximately 15% volume growth at the company level in FY 2027, with specific product segments like ATBS, IB, HP-MTBE, and customized products expected to contribute significantly. The company plans to invest INR 200-250 crores in capex for FY 2027, focusing on capacity expansion, innovation, a
— This quarter: missed
Against the confident, optimistic tone struck on the May concall, this quarter confirms the volume/demand recovery but contradicts the margin comfort — profitability is running below the guided band on cost pressure. No street consensus specific to this quarter surfaced, so the read is versus the company's own guidance: revenue on track, margins missed. Corporate actions this quarter — the ₹17.11 Cr injection into a WoS (Jul 15) and ₹19.88 Cr into the Veeral Organics rights issue (May 18) — reinforce that the consolidated drag is deliberate capex/ramp spend, in line with the ₹200-250 Cr FY27 capex plan, with new-product revenue guided only from Q3 FY27. There were no exceptional items on either side, so reported and underlying growth are the same.
W1
Margin recovery toward the guided 26-27% EBITDA band — Q1 landed ~24.5%; watch whether input-cost pass-through improves in Q2
W2
New-product revenue that management guided from Q3 FY27 onwards, funded by the ₹200-250 Cr FY27 capex
W3
Consolidated-vs-standalone gap: whether Veeral Organics / Vinati USA start narrowing the ~₹15 Cr PAT drag as they ramp
Digitally-native filing, all columns/headers clear; both checks pass (Std 697.75+8.85=706.60, PBT164.90-tax41.34=123.56; Con 695.91+9.00=704.91, 147.76-38.90=108.86). No exceptional items either side. Consolidated PAT lags standalone (123.56) as WoS Veeral Organics/Vinati USA are in investment/ramp phase; foreign subsidiary added Rs5.96 Cr revenue, Rs0.91 Cr PAT.